Novanta Inc.
Rank #350HypergrowthNOVTU · Nasdaq · Technology
Novanta Inc. (NOVTU) — Rank #350 by gross profitability (GP/assets 0.20) · ROE 3.3% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001076930 · all metrics point-in-time as of the filing date.
About
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.
Show moreShow less
The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc.
was incorporated in 1968 and is based in Bedford, Massachusetts.
- Industry
- Scientific & Technical Instruments
- Sector
- Technology
- State
- A3
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- novanta.com
Financials
Weakening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilitydeteriorating
- Net cashdeteriorating
- Operating marginimproving
- Return on equitydeteriorating
- Share count (dilution)deteriorating
Red flags: fcf_ni_divergence_unfavorable
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2020-12-31filed 2021-03-01 | 2019-12-31filed 2020-02-26 | 2018-12-31filed 2019-02-27 | 2017-12-31filed 2018-02-28 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 590.6 | 626.1 | 614.3 | 521.3 |
| Revenue growth (YoY) | 53.5% | 62.7% | 59.7% | 35.5% |
| Gross profit | 244.5 | 262.1 | 261.5 | 220.5 |
| Gross margin | 41.4% | 41.9% | 42.6% | 42.3% |
| Net income | 44.5 | 40.8 | 49.1 | 60.1 |
| Net margin | 7.5% | 6.5% | 8.0% | 11.5% |
| EPS (diluted) | $1.25 | $1.15 | $1.43 | $1.13 |
| EPS growth (YoY) | 8.7% | -19.6% | 26.5% | — |
| Cash flow | ||||
| Operating cash flow | 140.2 | 63.2 | 89.6 | 63.4 |
| Capital expenditures | 10.5 | 10.7 | 14.7 | 9.1 |
| Free cash flow | 129.7 | 52.5 | 75.0 | 54.3 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?